APA

Nicholls S. J., Cavender M. A., Kastelein J. J. P., Schwartz G., Waters D. D., Rosenson R. S., Bash D. & Hislop C. (20120626). Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. : Cardiovascular drugs and therapy.

Chicago

Nicholls Stephen J, Cavender Matthew A, Kastelein John J P, Schwartz Gregory, Waters David D, Rosenson Robert S, Bash Dianna and Hislop Colin. 20120626. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. : Cardiovascular drugs and therapy.

Harvard

Nicholls S. J., Cavender M. A., Kastelein J. J. P., Schwartz G., Waters D. D., Rosenson R. S., Bash D. and Hislop C. (20120626). Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. : Cardiovascular drugs and therapy.

MLA

Nicholls Stephen J, Cavender Matthew A, Kastelein John J P, Schwartz Gregory, Waters David D, Rosenson Robert S, Bash Dianna and Hislop Colin. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. : Cardiovascular drugs and therapy. 20120626.